{
    "nctId": "NCT03767335",
    "briefTitle": "MEN1611 With Trastuzumab (+/- Fulvestrant) in Metastatic Breast Cancer",
    "officialTitle": "Open-label, Multicentre, Phase Ib Dose-escalation Study of MEN1611, a PI3K Inhibitor Combined With Trastuzumab With or Without Fulvestrant, in Subjects With PIK3CA Mutated HER2 Positive Locally Recurrent Unresectable (Advanced) or Metastatic (a/m) Breast Cancer Progressed to Anti-HER2 Based Therapy",
    "overallStatus": "COMPLETED",
    "conditions": "Advanced or Metastatic Breast Cancer",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "NA",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 62,
    "primaryOutcomeMeasure": "Maximum Tolerated Dose (MTD) and Recommended Phase 2 dose (RP2D)",
    "eligibilityCriteria": "Main Inclusion Criteria:\n\n* Histologically confirmed invasive adenocarcinoma of the breast\n* Known HER2+ breast cancer\n* Advanced or metastatic breast cancer harbouring PIK3CA mutation on tissue sample\n* \\> 2 lines of anti-HER2 based regimens with at least 1 regimen with trastuzumab\n* Radiological documented evidence of progressive disease\n* Life expectancy \u2265 12 weeks\n* Eastern Cooperative Oncology Group (ECOG) performance status \u2264 2\n\nMain Exclusion Criteria:\n\n* Previous treatment with PI3K inhibitors\n* Brain metastases untreated, unless treated \\> 4 weeks and only if clinically stable and not receiving corticosteroids\n* History of clinically significant bowel disease\n* \u2265 grade 2 diarrhoea\n* History of significant, uncontrolled, or active cardiovascular disease\n* Any serious and/or unstable pre-existing psychiatric or neurologic illness or other conditions that could interfere with patient's safety\n* Not controlled diabetes mellitus (glycated haemoglobin \\[HbA1c\\] \\>7%) and fasting plasma glucose \\>126 mg/dL\n* Concurrent chronic treatment with steroids, as immunosuppressant, or another immunosuppressive agent",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}